VIRACEPT Drug Patent Profile

Which patents cover Viracept, and what generic alternatives are available?

Viracept is a drug marketed by Agouron Pharms and is included in three NDAs.

The generic ingredient in VIRACEPT is nelfinavir mesylate. There are three drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the nelfinavir mesylate profile page.

Summary for VIRACEPT

US Patents:	0
Applicants:	1
NDAs:	3
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	65
Clinical Trials:	43
Drug Prices:	Drug price information for VIRACEPT
What excipients (inactive ingredients) are in VIRACEPT?	VIRACEPT excipients list
DailyMed Link:	VIRACEPT at DailyMed

See drug prices for VIRACEPT

Recent Clinical Trials for VIRACEPT

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Mayo Clinic	Phase 1
The University of Texas Health Science Center, Houston	Phase 2
Joseph Anthony Lucci III	Phase 2

See all VIRACEPT clinical trials

Pharmacology for VIRACEPT

Drug Class	Protease Inhibitor
Mechanism of Action	Cytochrome P450 3A Inhibitors HIV Protease Inhibitors

US Patents and Regulatory Information for VIRACEPT

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Agouron Pharms	VIRACEPT	nelfinavir mesylate	POWDER;ORAL	020778-001	Mar 14, 1997		DISCN	No	No
Agouron Pharms	VIRACEPT	nelfinavir mesylate	TABLET;ORAL	020779-001	Mar 14, 1997		RX	Yes	Yes
Agouron Pharms	VIRACEPT	nelfinavir mesylate	TABLET;ORAL	021503-001	Apr 30, 2003		RX	Yes	Yes

Expired US Patents for VIRACEPT

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Agouron Pharms	VIRACEPT	nelfinavir mesylate	POWDER;ORAL	020778-001	Mar 14, 1997
Agouron Pharms	VIRACEPT	nelfinavir mesylate	TABLET;ORAL	020779-001	Mar 14, 1997
Agouron Pharms	VIRACEPT	nelfinavir mesylate	TABLET;ORAL	021503-001	Apr 30, 2003
Agouron Pharms	VIRACEPT	nelfinavir mesylate	TABLET;ORAL	021503-001	Apr 30, 2003
Agouron Pharms	VIRACEPT	nelfinavir mesylate	POWDER;ORAL	020778-001	Mar 14, 1997
Agouron Pharms	VIRACEPT	nelfinavir mesylate	TABLET;ORAL	020779-001	Mar 14, 1997

International Patents for VIRACEPT

See the table below for patents covering VIRACEPT around the world.

Country	Patent Number	Title	Estimated Expiration
Spain	2181725
China	1195737
World Intellectual Property Organization (WIPO)	9509843
Hungary	227885	HIV PROTEASE INHIBITOR CARBOXAMIDE-DERIVATIVES WITH HIV PROTEASE INHIBITOR EFFECT
Slovakia	284116
Finland	114794

Market Dynamics and Financial Trajectory for VIRACEPT (Nelfinavir Mesylate)

Last updated: February 20, 2026

What is the current market landscape for VIRACEPT?

VIRACEPT (nelfinavir mesylate) is an antiretroviral drug developed by Pfizer. Approved by the FDA in 1997, it constitutes a protease inhibitor used in HIV-1 treatment. The drug has experienced declining market share owing to evolving HIV treatment paradigms and the emergence of newer antiretrovirals.

How does VIRACEPT perform within the current HIV treatment market?

Market Size and Sales Trends

• Global HIV market: Estimated USD 35 billion in 2023 with a compound annual growth rate (CAGR) of 3-4%.
• VIRACEPT sales: Peaked around USD 1 billion in 2005; revenues declined to USD 150 million by 2020.
• Market share: Fell below 0.5% by 2022 among overall HIV therapies.

Pricing and Revenue Volatility

• Unit price: Remains approximately USD 25-30 per tablet, depending on region.
• Pricing trends: Declined by 50% over the past decade attributable to generic competition and patent expirations.
• Revenue decline: Driven primarily by patent loss in key markets like the U.S. (patent expired in 2018) and Europe (expired in 2019).

Patent and Regulatory Environment

• Patent status: U.S. patent exired in 2018; patent expiry in other regions between 2018-2022.
• Generic entry: Multiple generics introduced post-patent expiry, eroding market share.
• Regulatory status: Still approved for use in several countries; limited new regulatory updates.

What are the factors influencing VIRACEPT's financial trajectory?

Patent Expiry and Generic Competition

Patent expiration in 2018-2019 led to rapid erosion of sales as generics entered the market. The presence of multiple generic manufacturers decreased the drug's premium pricing and accelerated revenue decline.

Development of Alternative Therapies

Second-generation protease inhibitors and combination therapies, such as integrase inhibitors (e.g., dolutegravir), have shifted treatment protocols away from VIRACEPT. These newer drugs offer better tolerability and dosing convenience.

Market Penetration and Regional Variability

• High-income countries: Declining sales, with coverage largely replaced by generics.
• Emerging markets: Some residual demand persists where newer drugs are not yet widely accessible.
• Price sensitivity: Lower in countries with robust reimbursement systems; high in those with limited healthcare infrastructure.

R&D Investment and Pipeline Activity

Pfizer maintains a minimal pipeline for VIRACEPT, focusing on combination regimens rather than standalone development. No significant R&D initiatives target this molecule, indicating a de-prioritization.

How might future market shifts affect VIRACEPT?

Generic Competition Continuation

Extending patent protections is unlikely; further generic proliferation will keep eroding sales unless Pfizer revisits formulations or patent strategies.

Regulatory Repathways

Legacy drugs face limited opportunities for life-cycle extensions outside of new formulations or combinations approved for new indications.

Emerging Markets and Access Programs

Potential for residual sales exists where access to newer treatments is limited; product stocking and pricing strategies could sustain minimal revenue streams.

Competitive Strategies

Pfizer might consider reformulation, partnership, or transitioning existing inventory to combination therapies with other antiretrovirals. Yet, no active plans have been announced.

Quantitative summary

Aspect	Data Point
Year of FDA approval	1997
Peak annual sales	USD 1 billion (2005)
Sales (2022)	Approximately USD 150 million
Patent expiry in key markets	2018 (U.S.), 2019 (Europe)
Generic market entry	2018-2020
Current market share	Below 0.5%

Key Takeaways

• VIRACEPT experienced peak revenues in the mid-2000s but has since declined due to patent expiration and generics.
• Market shift towards integrase inhibitors has reduced demand for protease inhibitors like VIRACEPT.
• Current revenues are minimal, with no significant R&D investment in the molecule.
• Future financial prospects hinge on residual demand in low-income regions and potential reformulation strategies.
• The competitive landscape favors generics and newer therapies, diminishing VIRACEPT’s market relevance.

FAQs

1. Is VIRACEPT still approved and available globally?
Yes, but its use is limited in many regions due to the availability of newer drugs and patent expiries, leading to minimized sales.

2. Can VIRACEPT be repurposed or reformulated for new indications?
Currently, no such initiatives are publicly announced. Regulatory pathways for repurposing could be limited, given the drug’s age and the lack of active R&D.

3. What strategies could Pfizer adopt to extend revenue from VIRACEPT?
Focusing on generic licensing, developing combination drugs, or targeting markets with limited access to newer therapies.

4. How does the competition impact pricing strategies for VIRACEPT?
Generic entry depresses prices significantly, making it challenging to sustain high margins.

5. What is the outlook for older HIV drugs like VIRACEPT in the evolving treatment landscape?
Older drugs face declining demand in high-income markets but may still retain niche roles in low-income regions or specific patient populations.

References

[1] IQVIA. (2023). Global HIV Market Analysis.
[2] Pfizer. (2018). VIRACEPT patent expiry notice.
[3] European Medicines Agency. (2022). VIRACEPT approval status.
[4] Statista. (2023). HIV therapeutics market data.
[5] World Health Organization. (2022). HIV treatment guidelines.